Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Mar 27;17(1):62.
doi: 10.1186/s12883-017-0844-z.

Healthcare resource use and costs of multiple sclerosis patients in Germany before and during fampridine treatment

Tjalf Ziemssen  1 , Christine Prosser  2 , Jennifer Scarlet Haas  3 , Andrew Lee  4 , Sebastian Braun  2 , Pamela Landsman-Blumberg  5 , Angela Kempel  6 , Erika Gleißner  6 , Sarita Patel  6 , Ming-Yi Huang  4
Affiliations

Healthcare resource use and costs of multiple sclerosis patients in Germany before and during fampridine treatment

Tjalf Ziemssen et al. BMC Neurol. .

Abstract

Background: Multiple sclerosis (MS) patients often suffer from gait impairment and fampridine is indicated to medically improve walking ability in this population. Patient characteristics, healthcare resource use, and costs of MS patients on fampridine treatment for 12 months in Germany were analyzed.

Methods: A retrospective claims database analysis was conducted including MS patients who initiated fampridine treatment (index date) between July 2011 and December 2013. Continuous insurance enrollment during 12 months pre- and post-index date was required, as was at least 1 additional fampridine prescription in the fourth quarter after the index date. Patient characteristics were evaluated and pre- vs post-index MS-related healthcare utilization and costs were compared.

Results: A total of 562 patients were included in this study. The mean (standard deviation [SD]) age was 50.5 (9.8) years and 63% were female. In the treatment period, almost every patient had at least 1 MS-related outpatient visit, 24% were hospitalized due to MS, and 79% utilized MS-specific physical therapy in addition to the fampridine treatment. Total MS-related healthcare costs were significantly higher in the fampridine treatment period than in the period prior to fampridine initiation (€17,392 vs €10,960, P < 0.001). While this difference was driven primarily by prescription costs, MS-related inpatient costs were lower during fampridine treatment (€1,333 vs €1,565, P < 0.001).

Conclusions: Physical therapy is mainly used concomitant to fampridine treatment. While healthcare costs were higher during fampridine treatment compared to the pre-treatment period, inpatient costs were lower. Further research is necessary to better understand the fampridine influence.

Keywords: Claims data; Fampridine; Germany; Multiple sclerosis.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
MS-related resource utilization in the 12 months before and during fampridine treatment
Fig. 2
Fig. 2
Subgroups
Fig. 3
Fig. 3
MS-related healthcare costs by subgroup during fampridine treatment
See this image and copyright information in PMC

References

    1. Paltamaa J, Sarasoja T, Leskinen E, Wikstrom J, Malkia E. Measures of physical functioning predict self-reported performance in self-care, mobility, and domestic life in ambulatory persons with multiple sclerosis. Arch Phys Med Rehabil. 2007;88(12):1649–57. doi: 10.1016/j.apmr.2007.07.032. - DOI - PubMed
    1. Panitch H, Applebee A. Treatment of walking impairment in multiple sclerosis: an unmet need for a disease-specific disability. Expert Opin Pharmacother. 2011;12(10):1511–21. doi: 10.1517/14656566.2011.586338. - DOI - PubMed
    1. Zwibel HL. Contribution of impaired mobility and general symptoms to the burden of multiple sclerosis. Adv Ther. 2009;26(12):1043–57. doi: 10.1007/s12325-009-0082-x. - DOI - PubMed
    1. Van Asch P. Impact of mobility impairment in multiple sclerosis 2-patients’ perspectives. Eur Neurol Rev. 2011;6(2):115–20. doi: 10.17925/ENR.2011.06.02.115. - DOI
    1. Larocca NG. Impact of walking impairment in multiple sclerosis: perspectives of patients and care partners. Patient. 2011;4(3):189–201. doi: 10.2165/11591150-000000000-00000. - DOI - PubMed